Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4104)
All Articles published online
|
Jul 28, 2008 (publication date) through May 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Stolfi C, Pellegrini R, Franzè E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 2008; 14(28): 4434-4439 [PMID: 18680220 DOI: 10.3748/wjg.14.4434] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i28/4434.htm |
| Number | Citing Articles |
| 1 |
Joanna Słoka, Marcel Madej, Barbara Strzalka-Mrozik. Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer. Molecules 2023; 28(13): 5081 doi: 10.3390/molecules28135081
|
| 2 |
Jae Hee Cheon. Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists. Journal of Rheumatic Diseases 2021; 28(1): 4 doi: 10.4078/jrd.2021.28.1.4
|
| 3 |
Venkataraman Subramanian, Richard F. Logan. Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Practice & Research Clinical Gastroenterology 2011; 25(4-5): 593 doi: 10.1016/j.bpg.2011.09.003
|
| 4 |
Maximilian Hoffmann, Theresa A. Kant, Ramona Emig, Johanna S. E. Rausch, Manja Newe, Mario Schubert, Karolina Künzel, Luise Winter, Erik Klapproth, Rémi Peyronnet, Ursula Ravens, Ali El-Armouche, Stephan R. Künzel. Repurposing mesalazine against cardiac fibrosis in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology 2021; 394(3): 533 doi: 10.1007/s00210-020-01998-9
|
| 5 |
Rishu Dheer, Julie M. Davies, Maria T. Abreu. Intestinal Tumorigenesis. 2015; : 211 doi: 10.1007/978-3-319-19986-3_8
|
| 6 |
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis. 2017; : 389 doi: 10.1007/978-3-319-33703-6_38
|
| 7 |
Lily P.H. Yang, Paul L. McCormack. MMX® Mesalazine. Drugs 2011; 71(2): 221 doi: 10.2165/11205870-000000000-00000
|
| 8 |
Balakrishnan S. Ramakrishna, Govind K. Makharia, Philip Abraham, Uday C. Ghoshal, Venkataraman Jayanthi, Brij Kishore Agarwal, Vineet Ahuja, Deepak K. Bhasin, Shobna J. Bhatia, Gourdas Choudhuri, Sunil Dadhich, Devendra C. Desai, Gopal Krishna Dhali, Bhaba Dev Goswami, Sanjeev K. Issar, Ajay K. Jain, Rakesh Kochhar, Ajay Kumar, Goundappa Loganathan, Sri Prakash Misra, C. Ganesh Pai, Sujoy Pal, Anna Pulimood, Amarender S. Puri, Ganesh N. Ramesh, Gautam Ray, Shivaram P. Singh, Ajit Sood, Manu Tandan. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian Journal of Gastroenterology 2012; 31(6): 307 doi: 10.1007/s12664-012-0259-0
|
| 9 |
A. LYAKHOVICH, C. GASCHE. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Alimentary Pharmacology & Therapeutics 2010; 31(2): 202 doi: 10.1111/j.1365-2036.2009.04195.x
|
| 10 |
Sung-hee Han, Jonghun Lee. Chemoprevention of Colorectal Cancer in Inflammatory Bowel Disease. The Korean Journal of Gastroenterology 2014; 63(1): 3 doi: 10.4166/kjg.2014.63.1.3
|
| 11 |
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis. 2012; : 453 doi: 10.1007/978-1-4614-0998-4_36
|
| 12 |
Nonna Ogurchenok, Konstantin Khalin, Igor Bryukhovetskiy. Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review). Medicine International 2024; 4(3) doi: 10.3892/mi.2024.149
|
| 13 |
Xi Yang, Fengyi Zhang, Yajing Wang, Min Cai, Qing Wang, Qinglong Guo, Zhiyu Li, Rong Hu. Oroxylin A Inhibits Colitis-associated Carcinogenesis Through Modulating the IL-6/STAT3 Signaling Pathway. Inflammatory Bowel Diseases 2013; : 1 doi: 10.1097/MIB.0b013e318293c5e0
|
| 14 |
I. KÜBLER, M. J. KOSLOWSKI, M. GERSEMANN, K. FELLERMANN, J. BEISNER, S. BECKER, K. ROTHFUSS, K. R. HERRLINGER, E. F. STANGE, J. WEHKAMP. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease. Alimentary Pharmacology & Therapeutics 2009; 30(6): 621 doi: 10.1111/j.1365-2036.2009.04070.x
|
| 15 |
Carmine Stolfi, Roberta Caruso, Eleonora Franzè, Angelamaria Rizzo, Angela Rotondi, Ivan Monteleone, Massimo Claudio Fantini, Francesco Pallone, Giovanni Monteleone. 2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression. Molecular Cancer Therapeutics 2011; 10(10): 1969 doi: 10.1158/1535-7163.MCT-11-0316
|
| 16 |
S Danese, A Mantovani. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer. Oncogene 2010; 29(23): 3313 doi: 10.1038/onc.2010.109
|
| 17 |
Ming-zhe Ma, Gang Chen, Peng Wang, Wen-hua Lu, Chao-feng Zhu, Ming Song, Jing Yang, Shijun Wen, Rui-hua Xu, Yumin Hu, Peng Huang. Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Letters 2015; 368(1): 88 doi: 10.1016/j.canlet.2015.07.031
|
| 18 |
S. PARENTI, F. FERRARINI, R. ZINI, M. MONTANARI, L. LOSI, B. CANOVI, S. FERRARI, A. GRANDE. Mesalazine inhibits the β‐catenin signalling pathway acting through the upregulation of μ‐protocadherin gene in colo‐rectal cancer cells. Alimentary Pharmacology & Therapeutics 2010; 31(1): 108 doi: 10.1111/j.1365-2036.2009.04149.x
|
| 19 |
Shafina Siddiqui, Ankita Jaywant Deshmukh, Priyanka Mudaliar, Apoorva Jagannath Nalawade, Deepak Iyer, Jyotirmoi Aich. Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review. Journal of the Egyptian National Cancer Institute 2022; 34(1) doi: 10.1186/s43046-022-00137-0
|
| 20 |
Cristiana Perrotta, Paolo Pellegrino, Eliana Moroni, Clara De Palma, Davide Cervia, Piergiorgio Danelli, Emilio Clementi. Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/456895
|
| 21 |
Shun-Wen Hsiao, Hsu-Heng Yen, Yang-Yuan Chen. Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease. Gut and Liver 2022; 16(6): 840 doi: 10.5009/gnl210479
|
| 22 |
|
| 23 |
Song I Bae, You Sun Kim. Colon Cancer Screening and Surveillance in Inflammatory Bowel Disease. Clinical Endoscopy 2014; 47(6): 509 doi: 10.5946/ce.2014.47.6.509
|
| 24 |
Hyun-Young Kim, Se-Lim Kim, Young-Ran Park, Yu-Chuan Liu, Seung Young Seo, Seong Hun Kim, In Hee Kim, Seung Ok Lee, Soo Teik Lee, Sang Wook Kim. Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells. Intestinal Research 2015; 13(3): 233 doi: 10.5217/ir.2015.13.3.233
|
| 25 |
Maximilian J. Waldner, Stefan Wirtz, André Jefremow, Moritz Warntjen, Clemens Neufert, Raja Atreya, Christoph Becker, Benno Weigmann, Michael Vieth, Stefan Rose-John, Markus F. Neurath. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. Journal of Experimental Medicine 2010; 207(13): 2855 doi: 10.1084/jem.20100438
|
| 26 |
Marios Efthymiou, Andrew C.F. Taylor, Michael A. Kamm. Cancer surveillance strategies in ulcerative colitis. Inflammatory Bowel Diseases 2011; 17(8): 1800 doi: 10.1002/ibd.21540
|
| 27 |
Hans Herfarth, Stephan R. Vavricka. 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?. Inflammatory Intestinal Diseases 2022; 7(1): 28 doi: 10.1159/000518865
|
| 28 |
Darla R. Shores, David G. Binion, Bruce A. Freeman, Paul R.S. Baker. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflammatory Bowel Diseases 2011; 17(10): 2192 doi: 10.1002/ibd.21560
|